Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cigna: US Adalimumab Prices Could Vary Meaningfully

‘A Lot Of Dust Needs To Settle,’ US Insurance Giant Says

Executive Summary

Cigna has responded to several questions from the insurer/payer side on the potential effect of multiple biosimilar Humira products launching in 2023 and beyond.

You may also be interested in...



Competition Intensifies As Access Increases For US Biosimilars

At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.

Teva: Payers Hold The Cards On Material 2023 Adalimumab Opportunity

Fresh from partner Alvotech resolving patent litigation in the US for its proposed Humira biosimilar, Teva management has detailed the firm’s expectations around the product and the crucial issue of supply.

AbbVie Focuses On Humira’s Formulary Positioning Ahead Of US Biosimilars

A year out from US competition to top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain for the originator until 2024.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

GB151978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel